title: Development and evaluation of fixed dose bi therapy sublingual tablets for treatment stress hypertension and anxiety.
abstract: OBJECTIVE
  A stress induced rise in the blood pressure. Some believe that patients with hypertension are characterized by a generalized state of increased anxiety.
  
  
  OBJECTIVE
  The purpose of this study is to prepare a fixed dose bi therapy using bisoprolol hemifumarate (BH) as antihypertensive drug and buspirone hydrochloride (BuHCl) as anxiolytic drug, which can be used to treat both diseases concomitantly. Using sublingual tablets is hopeful to improve the BuHCl poor oral bioavailability and to facilitate administration to patients experiencing problems with swallowing.
  
  
  METHODS
  A total of 5mg BH and 10mg BuHCl were selected based on compatibility study. A 3×22 full factorial design was adopted for the optimization of the tablets prepared by direct compression method. The effects of the filler type, the binder molecular weight, and the binder type were studied. The prepared formulae were evaluated according to their physical characters as hardness, friability, disintegration time (new modified method and in vivo disintegration time) and wetting properties. In vitro drugs dissolute, permeation through the buccal mucosa and the effect of storage were analyzed by a new valid high pressure liquid chromatography (HPLC) method. Bioavailability study of the selected formula study was carried out and followed by the clinical.
  
  
  RESULTS
  The optimized tablet formulation showed accepted average weight, hardness, wetting time, friability, content uniformity, disintegration time (less than 3 min). Maximum drug release could be achieved with in 10 min. In addition enhancing drug permeation through the buccal mucosa and, the maximum concentration of the drug that reached the blood was in the first 10 min which means a rapid onset of action and improved the extent of both drug's absorption.
  
  
  CONCLUSIONS
  The results revealed that sublingual (F6) tablets containing both drugs would maintain rapid onset of action, and increase bioavailability. BuHCl with BH can be attributed to the marked decline in DBP and SBP. That led to a reduction in the MAP.
authors.affiliation: Department of Pharmaceutics and Industerial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
authors.forename: Mohamed A
authors.initials: MA
authors.lastname: El-Nabarawi
authors.forename: Saadia A
authors.initials: SA
authors.lastname: Tayel
authors.forename: Nadia A
authors.initials: NA
authors.lastname: Soliman
authors.forename: Hadel A
authors.initials: HA
authors.lastname: Abo Enin
keywords: Bisoprolol hemifumarate; bioavailability study; buspirone hudrochloride; sublingual tablets; transmucosal study